CD117+ small cell lung cancer lacks the asp 816→val point mutation in exon 17

Histopathology

Volumn 47, Issue 5, 2005, Pages 517-522

  Mojica, Wilfrido D ^a   Saxena, R ^a   Starostik, P ^b   Cheney, R T ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

C kit; CD117; PCR; Small cell lung cancer

Indexed keywords

ASPARTIC ACID; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; VALINE;

ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; EMBEDDING; EXON; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; LUNG SMALL CELL CANCER; ONCOGENE C KIT; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TISSUE FIXATION;

CARCINOMA, SMALL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES;

EID: 27744596973     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02259.x     Document Type: Article

References (34)

1. Chute JP, Chen T, Feigel E et al. Twenty years of phase III trials for patients with extensive stage small cell lung cancer: perceptible progress. J. Clin. Oncol. 1999; 17; 1794-1801.
2. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 1991; 99; 1425-1432.
3. Buchdunger E, Cioffi CL, Law N et al. Abl protein tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 2000; 295; 139-145.
4. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001; 344; 1031-1037.
5. Carroll M, Ohno-Jones S, Tamura S et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing bcr-abl, tel-abl, and tel-pdgfr fusion proteins. Blood 1997; 90; 4947-4952,
6. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001; 344; 1052-1056.
7. Natali PG, Nicotra MR, Sures I et al. Expression of c-kit receptor in normal and transformed human non-lymphoid tissues. Cancer Res. 1992; 52; 6139-6143.
8. Turner AM, Zsebo KM, Martin F et al. Non-hematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992; 80; 374-381.
9. Micke P, Basrai M, Faldum A et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin. Cancer Res. 2003; 9; 188-194.
10. Naeem M, Dahiya M, Clark JI et al. Analysis of c-kit protein expression in small cell lung carcinoma and its implication for prognosis. Hum. Pathol. 2002; 33; 1182-1187.
11. Butnor KJ, Burchette JL, Sporn TA et al. CD117 immunoreactivity in pleuropulmonary tumors. Mod. Pathol. 2002; 15; 1317 (Abstract).
12. Nagata H, Worober AS, Oh CK et al. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Nat. Acad. Sci. USA 1995; 92; 10560-10564.
13. Schindler T, Bornmann W, Pellicena P et al. Structural mechanism for STI571 inhibition of Abelson tyrosine kinase. Science 2000; 289; 1938-1942.
14. Ma Y, Zeng S, Metcalfe DD et al. The c-kit mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild type kinases and those with regulatory type mutations. Blood 2002; 99; 1740-1744.
15. Heinrich MC, Blanke CD, Druker BJ et al. Inhibition of kit tyrosine kinase activity: a novel molecular approach to the treatment of kit-positive malignancies. J. Clin. Oncol. 2002; 20; 1692-1703.
16. www.genome.wi.mit.edu (last accessed August 2002).
17. Beswer P, Murphy JE, George PC et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986; 320 (6061); 415-421.
18. Yarden Y, Kuang WJ, Yang-Feng T et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987; 6; 3341-3351.
19. Lux ML, Rubin BP, Biase TL et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 2000; 156; 791-795.
20. Lev S, Givol D, Yarden Y. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. EMBO J. 1991; 10; 647-654.
21. Koch CA, Anderson D, Morgan MF et al. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 1991; 252 (5006); 668-674.
22. Pawson T. Protein modules and signaling networks. Nature 1995; 252 (6515); 573-580.
23. Maeda H, Yamagata A, Nishikawa S et al Requirement of c-kit for development of intestinal pacemaker system. Development 1992; 116; 369-375.
24. Lev S, Blechman JM, Givol D et al. Steel factor and c-kit proto-oncogene: genetic lessons in signal transduction. Crit. Rev. Oncog. 1994; 5; 141-168.
25. Buchdunger E, Zimmermann J, Mett T et al. Inhibition of the abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylamino-pyrimidine derivative. Cancer Res. 1996; 56; 100-104.
26. Deininger MWN, Goldman JM, Lydon N et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of bcr-abl positive cells. Blood 1997; 90; 3691-3698.
27. Artega CL, Khuri F, Krystal G, Sebti S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Sem. Oncol. 2002; 29 (1 Suppl. 4); 15-26.
28. Matsuda R, Takahashi T, Nakamura S et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am. J. Pathol. 1993; 142; 339-346.
29. Hirota S, Isozaki K, Moriyama Y et al. Gain of function mutation of c-kit in human gastrointestinal stromal tumors. Science 1998; 279; 577-580.
30. Nicholson SA, Beasley MB, Brambilla E et al. Small cell lung carcinoma. A clinicopathologic study of 100 cases with surgical specimens. Am. J. Surg. Pathol. 2002; 26; 1184-1197.
31. Williams C, Ponten F, Moberg C et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am. J. Pathol. 1999; 155; 1467-1471.
32. Ben-Ezra J, Johnson DA, Rossi J et al. Effect of fixation on the amplification of nucleic acids from paraffin-embedded material by the polymerase chain reaction. J. Histochem. Cytochem. 1991; 39; 351-354.
33. Greer CE, Wheeler CM, Manos MM. Sample preparation and PCR amplification from paraffin-embedded tissues. PCR Meth. Appl. 1994; 3 (Suppl.); S113-S122.
34. Morieira D. Efficient removal of PCR inhibitors using agarose-embedded DNA preparations. Nuc. Acid. Res. 1998; 26; 3309-3310.